NuVasive CEO Sells $1,173,301 in Stock (NUVA)
NuVasive (NASDAQ:NUVA) CEO Alexis Lukianov sold 34,217 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $34.29, for a total value of $1,173,300.93. Following the completion of the sale, the chief executive officer now directly owns 55,740 shares of the company’s stock, valued at approximately $1,911,325. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
NUVA has been the subject of a number of recent research reports. Analysts at Barclays raised their price target on shares of NuVasive from $32.00 to $35.00 in a research note to investors on Thursday. They now have an “equal weight” rating on the stock. Separately, analysts at Zacks downgraded shares of NuVasive from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, January 2nd. They now have a $35.40 price target on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $29.34.
Shares of NuVasive (NASDAQ:NUVA) traded up 0.48% during mid-day trading on Thursday, hitting $35.23. 374,672 shares of the company’s stock traded hands. NuVasive has a 52 week low of $16.57 and a 52 week high of $35.38. The stock has a 50-day moving average of $32.69 and a 200-day moving average of $27.43. The company’s market cap is $1.572 billion.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.39 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.24 by $0.15. The company had revenue of $169.20 million for the quarter, compared to the consensus estimate of $158.30 million. During the same quarter last year, the company posted $0.23 earnings per share. NuVasive’s revenue was up 14.0% compared to the same quarter last year. Analysts expect that NuVasive will post $1.14 EPS for the current fiscal year.
NuVasive, Inc (NASDAQ:NUVA) is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.